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 Supplementary Methods: 
 
Supplementary Method I: Synthesis of DNA-capture antibody conjugates.  
As-received antibodies (SI Appendix, Table S1) were desalted, buffer exchanged to pH 
7.4 PBS and concentrated to 0.5 mg/mL using Zebba protein desalting spin columns 
(Pierce). Succinimidyl 4-hydrazinonicotinate acetone hydrazone in N,N-
dimethylformamide (DMF) (SANH, Solulink) was added to the antibodies at variable 
molar excess of (300:1) of SANH to antibody. Separately, succinimidyl 4-
formylbenzoate in DMF (SFB, Solulink) was added at a 16-fold molar excess to 
5‘aminated 30mer oligomers in PBS. After incubation for 4h at room temperature, excess 
SANH and SFB were removed and both samples buffered exchanged to pH 6.0 citrate 
buffer using protein desalting spin columns. A 30-fold excess of derivative DNA was 
then combined with the antibody and allowed to react overnight at room temperature. 
Noncoupled DNA was removed using a Pharmacia Superdex 200 gel filtration column 
(GE) at 0.5 mL/min isocratic flow of PBS. The conjugates were then concentrated to 0.5 
mg/mL by Amicon Ultra-4 Centrifugal Filter Unit with Ultracel-10 membrane (Millipore 
10kDa) and stored at 4°C. The conjugation yield was determined by Nanodrop (Thermal 
Scientific). Detailed protocol can be found in the Protein-Oligo Conjugation Kit 
(Solulink).  
 
Supplementary Method II: Protocols of single cell proteomic assay. 
The procedures of using an SCBC for profiling secreted and intracellular proteins from 
single cells are as follows: 
a)  Prior to cell loading, all microfluidic channels were blocked with a blocking 
buffer (3% bovine serum albumin (BSA, Sigma-Aldrich) in 1X PBS) for 60 minutes.  
b) Conversion of the DNA barcodes to capture antibody microarrays: A cocktail 
containing all DNA-antibody conjugates was introduced through the upper assay 
channels of the SCBC and incubated at 37°C for 60 minutes. This transformed the 
DNA barcode microarrays into antibody microarrays for the subsequent surface-bound 
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immunoassay. Simultaneous with this process, the concentrated cell lysis buffer (5X) 
with concentrated protease inhibitor and phosphatase inhibitor were loaded into the 
lower lysis buffer chambers while the valve 4 (SI Appendix, Fig. S1A) was kept closed 
by applying 20-22psi constant pressure. The lysis buffer was identical to that described 
above for the mTOR kinase inhibition assay. The unbound conjugates were removed by 
flowing the washing buffer (3% BSA in PBS) for 10 minutes. The DNA-antibody 
conjugate solution (100µL) was prepared by mixing all synthesized conjugates in the 
washing buffer with a final concentration of 10µg/ml of each conjugate. 
c) Cell loading and on-chip cell culture: U87 EGFRvIII cells were dissociated with 
trypsin (0.25%, ATCC) and EDTA, centrifuged at 4°C and suspended in DMEM with 
1% FBS at a concentration of 1000 cells/µl. Before cell loading, the channels were 
rinsed by medium. Then, cells were then loaded into the upper assay channels of the 
chip and the valve 3 (SI Appendix, Fig. S1 A and B) was closed to compartmentalize the 
SCBC fluidic network into 240 isolated microchambers. Images of each chamber were 
recorded using a CCD camera, and used later for cell counting. The chip was 
transferred into a custom-built hypoxic chamber within a few minutes after cell loading, 
for culturing at a specific pO2 for 7 hours. Due to the permeability of PDMS, 
microchambers reached a hypoxic environment (<3% O2) in less than 30 minutes. 
d) On-chip cell lysis and protein measurement: After culturing within the hypoxic 
chamber, the chip was placed on ice and the valve 4 was opened for on-chip diffusion 
of lysis buffer to the neighboring cell chambers (SI Appendix, Fig. S1 E). The chip was 
tilted to accelerate the lysis buffer diffusion. Diffusion was complete in 15 minutes, 
after which valve 4 was closed and the chip was incubated on ice for another 15 
minutes with shaking to complete the on-chip cell lysis. The chip was incubated at 
room temperature with shaking for 2 hours to complete the capture of target proteins by 
antibody microarrays within the microchambers. Afterwards, the unbound cell lysate 
was quickly removed by flowing washing buffer through the microchannels for 10 
minutes. 
e) Applying detection antibodies: A mixture of biotin-labeled detection antibodies 
was flowed into the assay channels of the chip for 60 minutes at room temperature to 
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complete the sandwich immunoassay. The detection antibody solution contained 
biotinylated detection antibodies at a concentration specified in the insert of that ELISA 
kit (See the table above for reagents. The concentration varies from lot to lot). Unbound 
detection antibodies were then flushed out by flowing the washing buffer for 10 
minutes. 
f)  Fluorescence probe: Cy5 fluorescent dye-labeled streptavidin (eBioscience, 
2µg/ml) and the reference, Cy3-labeled complementary ssDNA (DNA code M/M' 
25nM) were combined in the washing buffer and flowed into the chip for 60 minutes. 
Afterwards, washing buffer was flowed for 20 minutes to remove unbound 
Streptavidin-Cy5. 1X Phosphate Buffered Saline Tween-20 (PBST) was then flowed 
for 45 minutes as the final wash step. 
g) Rinse: the PDMS device was peeled from the DNA patterned glass slide, and that 
slide was immediately dipped 3× each in the following solutions in order, 1X PBS, 
0.5X PBS, deionized Millipore water. The slide was then dried under flowing N2. 
h) Optical readout: The slide was scanned by an Axon GenePix 4400A (Molecular 
Devices) at laser power 80% (635nm) and 10% (532nm), and at 2.5 μm resolution. Two 
color channels (the green Cy3 and the red Cy5) collected fluorescence signals. The 
average fluorescence signals for all bars within a given barcode were extracted by a 
custom MATLAB (The Mathworks) code for further analysis. 
 
Supplementary Method III: Steady-state kinetic model. 
We first address the relationship between HIF-1α and pO2. Under normoxic conditions, 
HIF-1α is hydroxylated at conserved proline residues by HIF prolyl-hydroxylases 
(PHD1-3), allowing its further ubiquitination and degradation (1). But HIF-1α is 
stabilized in hypoxic environments because HIF prolyl-hydroxylase utilizes oxygen as a 
co-substrate, and so is inhibited at a low pO2 (2). It has also been reported that the 
formation of HIF-1α is directly regulated by NF-κB (3), while the activation of NF-κB is 
strongly related to the production of reactive oxygen species (ROS) (4). Therefore, it is 
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reasonable to assume that the production of HIF-1α is partially related to oxygen 
concentration. 
Thus, at steady state of HIF-1α ([HIF-1] for short), 
 'HIF 2 HIF HIF 2
[HIF-1] [O ][HIF-1] ( [O ]) 0d k P k
dt
                      (1) 
where HIFk is the rate constant for HIF-1α hydroxylation. The term 
'
HIF HIF 2[O ]P k represents the formation rate of HIF-1α that is partially dependent upon 
pO2. 
From Eq. 1, the steady-state HIF-1α concentration, which fits well with the experimental 
data (Fig. 4B),  is given by: 
 
'
HIF HIF 2
HIF 2
[O ][HIF-1]
[O ]
P k
k
                                                     (2) 
The level of p-mTOR in non-drug treated sample at a fixed pO2 is written as: 
 phos dephos
[p- mTOR] [mTOR] [p- mTOR] 0d k k
dt
             (3) 
where phosk is the phosphorylation constant of mTOR by phosphorylases or kinases and 
dephosk  is the de-phosphorylation constant of p-mTOR by phosphatases in a cell. Thus, as 
expected, the steady-state concentration of p-mTOR for non-drug treated sample is 
simply proportional to total mTOR concentration 
 phos dephos[p- mTOR] ( / )[mTOR]k k                          (4) 
Introduction of PP242 inhibits mTORC1 activity and down regulates mTOR S2448 
phosphorylation (5), which is equivalent to reducing phosk to a smaller value, 
PP242
phosk . Thus 
we have 
 PP242 p-mTORphos phos PP242[p- mTOR]'/ [p- mTOR] /k k    (5) 
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Since the oxygen dependent mTORC1 regulation and the drug inhibition of mTOR are 
independent processes, we take the inhibition constant p-mTORPP242 as independent of pO2, and 
so it can be readily calculated from experiment data. 
We now turn towards quantifying the dependence of [p-mTOR] on [HIF-1] for non-drug 
treated samples (Fig. 4C). These two proteins exhibit a clear (inverse) linear relationship, 
and so the plot is fitted using:  
 
p-mTOR 0
HIF[p- mTOR] [HIF-1] [p- mTOR]                  (6) 
where [p-mTOR]0 is the extrapolated concentration of p-mTOR at zero concentration of 
HIF-1α, and p-mTORHIF captures the strength of the inhibition of p-mTOR by HIF-1α 
dependent transcriptional regulations. 
Eq. 6 describes the increase in p-mTOR with decreasing HIF-1α.  PP242 further inhibits 
HIF-1α, which thus tends to promote p-mTOR.   
 p-mTOR p-mTORHIF PP242Promotion [HIF-1]                     (7) 
 where PP242 PP242[HIF-1] [HIF-1] [HIF-1]   is the inhibitory influence of the mTOR 
inhibitor PP242 on HIF-1α. To determine this value, we note that, for our experiments, 
PP242 concentration was either 0 (the DMSO control) or 3µM, while HIF-1α (through 
the influence of hypoxia) varied from around 800 to 2800 pg/ml. Over range, the 
suppression of HIF-1α by PP242 appears to quadratic with respect to HIF-1α 
concentration for non-drug treated samples (Fig. 4D). 
 HIF 2PP242 PP242[HIF-1] [HIF-1]                                  (8) 
As a result, according to the proposed mechanism, the p-mTOR concentration at different 
pO2 for PP242 treated cells is given by 
 p-mTOR p-mTOR242[p- mTOR] [p- mTOR] Inhibition PromotionPP       (9) 
where p-mTOR p-mTORpp242Inhibition ([p-mTOR] [p-mTOR]') (1 )[p- mTOR]    represents the 
direct inhibition on mTORC1 by PP242. 
The parameters used in the model are extracted from fits to the experimental data (Fig. 
4B–4D), and are provided in the table below. With these relationships, it is 
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straightforward to calculate the p-mTOR concentrations from only the pO2 values, the 
presence or absence of PP242, and the fitted parameters through eq. 9 (Fig. 4E). 
The following are parameters used in the steady-state kinetic model. 
parameters values 
PHIF 1877.8 pg/mL·s 
kHIF 100 s-1 
k'HIF'
 
83580 pg/mL·s 
[p-mTOR]0 3242 pg/mL 
p-mTOR
HIF  0.47 
p-mTOR
PP242  0.88 
HIF
PP242  9.8e-5 mL/pg 
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Supplementary Figures 
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Fig. S1. Single Cell Barcode Chip (SCBC) details. (A) The SCBC microfluidic chip 
design for enabling on-chip cell culture, cell lysis and multiplex protein detection. V1 to 
V6 represent inputs for activating specific valves. V3 isolates the chambers from the 
microchannels and V4 controls the diffusion between the cell chambers and the lysis 
buffer chambers. V1, V2, V5 and V6 control flow within the microchannels. (B) Cell 
viability check by trypan blue diffusion. Left is an optical image showing that the U87 
EGFRvIII cells attach to the collagen coated surface of an isolated microchamber in an 
SCBC device (upper) after 7 hours of on-chip culture at 1% pO2, while the neighboring 
chamber (lower) is filled with trypan blue with the inter-chamber valve closed. The 
image at right shows that opening the valve allows diffusion of trypan blue to the upper 
cell chamber. The undyed cells (plus their adherent and spread morphologies) indicate 
that the cells are viable after 7 hours of hypoxic incubation. (C) Quality assessments of 
the DNA barcode microarrays used for the SCBC assays. At left are fluorescence images 
of the DNA barcode stripes across the slide surface, with an intensity profile shown at 
right. This data reflects the uniform DNA loading across the whole slide. An Axon 
GenePix 4400A (Molecular Devices) array scanner was used to obtain this image in the 
532nm channel with a laser power set at 15% and an optical gain of 450. (D) An 
illustration of the sandwich-type immunoassay, based upon the DEAL approach that 
utilizes DNA hybridization to construct capture antibody arrays within a microfluidic 
chip. (E) Visualization of on-chip lysis buffer diffusion. Red food dye was used to 
visualize the diffusion process. The chip was cooled to ice temperatures and tilted to 
accelerate on-chip diffusion.  Those conditions are reflective of an actual experiment. 
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Fig. S2. (A) Data of secreted and cytoplasmic proteins profiling from individual SCBC 
microchambers containing single or few cells at different pO2 values, presented as a heat 
map. Columns containing 1-, 2- and 3-cell data are indicated by the color code along the 
top row. The heat maps were generated by Cluster and Treeview (EisenSoftware). (B) 
Antibody microarray utilized for both the multiplex protein assays from statistical 
numbers of cells, as well as for cross-reactivity checks of the assayed protein panel. 
Layout (left-top) and photograph (left-bottom) of the microarray. The layout inset shows 
a basic 13-spot repeat unit. Locations #A to #M are spotted with the same ssDNA 
oligomers that are used for DNA barcode SCBC microarrays. Spot diameters are 150 µm. 
The basic unit is repeated over 60 columns and 50 rows. The 12-well PDMS slab (left-
bottom) is bonded to the array-spotted glass slide. Each well has a volume of 50 µl and 
contains 5 complete sets of 13 DNA spots for simultaneously assaying the entire panel of 
proteins. At right is presented the cross-reactivity data for the panel of assayed proteins. 
For each row in the figure, the full cocktail of antibody-DNA conjugates (for the 7 
assayed proteins, except p-EGFR due to lack of standard protein) was used. One standard 
protein was tested per row. The red spots are signal from the standard proteins and the 
green spots are alignment reference signals from Cy3-labeled DNA sequence 
complementary to spot #M. The p-EGFR antibody does not cross-react with other 
proteins in the panel. (C) Calibrations of the assayed protein panel. The calibrations at 
left were carried out using SCBC barcodes within an SCBC, and under conditions similar 
to those single cell experiments, except that standard proteins were used. The calibration 
at right utilized the microwell format of the spotted arrays, and provides calibration data 
for the bulk cell assays. These curves are utilized to transform the fluorescence intensities 
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into concentrations (or copy numbers) of proteins. The error bars represent the standard 
deviations of the measurements. Two dagger symbols, color coded for each curve, are 
drawn to delineate the upper and lower range of protein levels that were detected within 
the experiments. For both the SCBC and bulk assays, these ranges are generally within 
the linear response regime of the calibration curves. Note that p-EGFR was not included 
here due to lack of standard protein. 
 
  
Fig. S3. The protein compositions of the 7 eigenvectors of the covariance matrix, as a 
function of pO2. Note that below 2% pO2, VEGF is almost completely decoupled from 
the other proteins, as indicated by its dominance within the 1st (highest amplitude) 
eigenvector.  
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Supplementary Tables 
Table S1. Reagents Used in this study. The upper table provides the sequences of the 
oligonucleotides used in the protein immunoassays. All oligonucleotides were 
synthesized by Integrated DNA Technology (IDT) and purified via high performance 
liquid chromatography (HPLC). The DNA coding oligomers were pre-tested for 
orthogonality to ensure that cross-hybridization between non-complementary oligomer 
strands was negligible (<1% in photon counts). Below the oligonucleotides is a list of the 
antibodies and standard proteins used for the multiplex protein assay. 
 
Name DNA Sequence Melting Point 
B 5'-AAA AAA AAA AGC CTC ATT GAA TCA TGC CTA -3' 57.4 
B' 5' NH3-AAA AAA AAA ATA GGC ATG ATT CAA TGA GGC -3' 55.9 
C 5'-  AAA AAA AAA AGC ACT CGT CTA CTA TCG CTA -3' 57.6 
C' 5' NH3-AAA AAA AAA ATA GCG ATA GTA GAC GAG TGC -3' 56.2 
D 5'- AAA AAA AAA AAT GGT CGA GAT GTC AGA GTA -3' 56.5 
D' 5' NH3-AAA AAA AAA ATA CTC TGA CAT CTC GAC CAT -3' 55.7 
E 5'- AAA AAA AAA AAT GTG AAG TGG CAG TAT CTA -3' 55.7 
E' 5' NH3-AAA AAA AAA ATA GAT ACT GCC ACT TCA CAT -3' 54.7 
G 5'-AAA AAA AAA AGA GTA GCC TTC CCG AGC ATT-3' 59.3 
G' 5' NH3-AAA AAA AAA AAA TGC TCG GGA AGG CTA CTC-3' 58.6 
H 5'-AAA AAA AAA AAT TGA CCA AAC TGC GGT GCG-3' 59.9 
H' 5' NH3-AAA AAA AAA ACG CAC CGC AGT TTG GTC AAT-3' 60.8 
K 5'-AAA AAA AAA ATA ATC TAA TTC TGG TCG CGG-3' 55.4 
K' 5' NH3-AAA AAA AAA ACC GCG ACC AGA ATT AGA TTA-3' 56.3 
L 5'-AAA AAA AAA AGT GAT TAA GTC TGC TTC GGC-3' 57.2 
L' 5' NH3-AAA AAA AAA AGC CGA AGC AGA CTT AAT CAC-3' 57.2 
M 5'-AAA AAA AAA AGT CGA GGA TTC TGA ACC TGT-3' 57.6 
M' 5' Cy3-AAA AAA AAA AAC AGG TTC AGA ATC CTC GAC-3' 56.9 
DNA label Antibody Source 
 
B' 
Capture: Human VEGF Antibody R&D MAB293 
Detection: Human VEGF 165 Biotinylated Antibody R&D BAF293 
Standard: Recombinant Human VEGF 165 R&D 293-VE 
C' Human p-mTOR (S2448) DuoSet® ELISA kit R&D DYC1665 
D' Human p-P70S6Kinase (T389) DuoSet® ELISA kit R&D DYC896 
 
E' 
Capture: Human IL-6 Antibody R&D MAB206 
Detection: Human IL-6 Biotinylated Antibody R&D BAF206 
Standard: Recombinant Human IL-6 R&D 206-IL 
G' Capture: Rabbit anti-human phospho-EGF R (Y1173) R&D AF1095 
Detection: Biotinylated Goat anti-human EGF R R&D BAF231 
H' Human p-ERK1 (T202/Y204) DuoSet® ELISA kit R&D DYC1825 
 
K' 
Capture: Human MMP-1 Antibody R&D AF901 
Detection: Human MMP-1 Biotinylated Antibody R&D BAF901 
Standard: Recombinant Human MMP-1 R&D 901-MP 
L' Human total HIF-1α DuoSet® ELISA kit R&D DYC1935 
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Table S2: Data and parameters used in protein calibration curves. Mean intensities and 
standard deviations of standard proteins and fitting parameters for bulk (upper half) and 
SCBC (lower half) calibration curves. The calibration curves for bulk protein 
measurements were fit by fourth order polynomials and those for SCBC protein 
measurements were well fit by a four parameter Morgan-Mercer-Flodin (MMF) model.  
 
Calibration curves for bulk protein measurement 
 p-ERK p-mTOR p-S6K HIF-1α MMP-1 VEGF IL-6 
50ng/ml 6433± 
93.2 
5216± 
208.5 
5758.2± 
558.8 
9586± 99.5 11224± 
1020.7 
40209± 
2289.7 
29293± 
1273.5 
10ng/ml 1608± 
110.5 
800.6± 
41.7 
1185± 
61.2 
1945.5± 
78.7 
1535.9± 
78.3 
6015± 
1201.3 
3525.4± 
133.4 
5ng/ml 743.8± 
44.3 
409.2± 
69.8 
456.7± 
32.7 
805.5± 
33.2 
660± 31.8 2417.8± 
141.6 
1250.5± 
50.6 
1ng/ml 149.2± 13 51.4± 
11.2 
105.4± 
16.4 
127.6± 
24.4 
129.7± 
10.6 
452±16.1 248.7± 
25.2 
500pg/ml 63.5± 12.5 29.5± 3.5 72.3± 7 53.3±6.7 74.8± 4.5 255.7± 
32.7 
132.8± 
13.5 
100pg/ml 20.6±1.6 13.8±0.4 37±7.3 11±1.1 21.2±2.5 79.6± 17.4 45±4.9 
10pg/ml 17.2± 2 12.4± 0.5 34.7± 4.2 7±0.8 8.6±2.4 66.3± 23.2 30.4± 7.7 
2 3 4y a bx cx dx ex      
 a b c d e r 
p-ERK 9.04 0.13 3.71E-6 -7.5E-11 0 0.9999 
p-mTOR 12.1 2.35E-2 1.8E-5 -1.47E-9 2.29E-14 0.9999 
p-S6K 32.6 7.39E-2 -2.87E-7 5.47E-10 -1.05E-14 0.9999 
HIF-1α 1.59 0.11 1.19E-5 -3.92E-10 3.72E-15 0.9999 
MMP-1 9.03 0.123 -5.56E-7 4.24E-10 -7.45E-15 0.9999 
VEGF 69.6 0.328 3.09E-5 -4.28E-10 0 0.9999 
IL-6 24.7 0.226 -6.84E-6 2.33E-9 -4.11E-14 0.9999 
 
Calibration curves for SCBC protein measurement
 p-ERK p-mTOR p-S6K HIF-1α MMP-1 VEGF IL-6 
50ng/ml 189.5± 7.7 170.6± 8.1 215.7± 5.1 248.6± 15.2 218.7± 14.8 254± 16.6 251.7± 4.3 
10ng/ml 81.3± 3.1 65.9± 3.5 85.1± 4.3 97.9± 5.4 83.5± 4 182.3± 6.8 240.7± 14.9 
1ng/ml 11.3± 0.63 12± 0.64 13± 1.02 16.8± 1.1 23.1± 1.6 70.7± 3.01 105.2± 6.05 
100pg/ml 2.76± 0.15 6.31± 0.77 2.41± 0.26 4.3±0.28 8.4±1.05 18.7±2.3 14.3± 1.31 
10pg/ml 2.28± 0.24 6.09± 0.64 1.98± 0.29 2.62± 0.28 5.1±0.47 5.1±0.33 8.12±0.81 
 
0 2.2± 0.24 6.08± 0.72 1.5± 0.17 2.05± 0.18 4.11±0.53 1.29±0.14 7.9±0.77 
d
d
ab cxy
b x
   
 a b c d r 
p-ERK 2.134 28.005 267.22 1.077 0.9999 
p-mTOR 5.997 41.482 261.08 1.105 0.9999 
p-S6K 1.518 31.53 370.82 0.965 0.9999 
HIF-1α 2.27 31.667 478.25 0.901 0.9999 
MMP-1 4.162 227.94 4267 0.637 0.9999 
VEGF 1.239 3.552 316.86 0.68 0.9999 
IL-6 8.124 1.524 253.24 1.443 0.9999 
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Table S3. Parameters used for the Monte Carlo simulation of the fluctuation profile of a 
hypothetical protein. 
Process Averaged required protein copy # Distribution type Fraction active 
Baseline 100 Gaussian  
Process-1 150 Gaussian 0.7 
Process-2 200 Gaussian 0.3 
Process-3 250 Gaussian 0.5 
Process-4 300 Gaussian 0.8 
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Table S4. Mean intensities and standard deviations for the SCBC protein assays from 
U87 EGFRvIII cells as a function of number of cells, and under different oxygen 
contents. 
 
cell ref p-EGFR p-ERK p-mTOR p-S6K MMP-1 HIF-1α VEGF IL-6 Copy # 
Normoxia condition at 21% O2, 7 hours incubation 
1 81.4±
5.9 
154.6±4
9.5 
12.2±4 18.8±9.1 13.5±4.3 33.8± 
16.8 
16.9±4.
2 
50.1±16 67.7±
38.6 
113 
2 81.2±
5.1 
190.6±3
8.6 
16.4± 6.4 28.5±19.
4 
17.3±7.6 38.2± 
14.1 
24.7±7.
1 
105.5±2
4.1 
123.8
±50.2 
43 
3 82.1±
6.2 
204.1±5
9.6 
23.7±9.5 38.4±19.
7 
23.5±9 44.8± 
28.9 
28.7±8.
1 
158.2±2
2.7 
179.3
±28.2 
40 
Hypoxia condition at 3.0% O2, 7 hours incubation 
1 80.6±
4 
150.9±5
2.6 
11.9±3.6 18.4±7.1 12.7±2.8 30.8± 9.9 24.9±7.
4 
85.4±32
.5 
79.6±
34.7 
77 
2 80.6±
4.8 
184.8±5
3.4 
17± 8.04 27.4±12.
8 
17.3±6.9 34.7±14.
9 
31±8.8 149.6±3
0.7 
141.9
±58.9 
61 
3 80.9±
4.2 
199.5±4
6.4 
23.2± 9.6 37.8±18.
9 
21.5±6.9 39.5±11.
4 
37.3±8.
2 
183.2±1
1.6 
192.9
±51.5 
23 
Hypoxia condition at 2.0% O2, 7 hours incubation 
1 80±4.
4 
161.4±5
1.6 
11.2±3.6 19.2±6.3 9.2± 2.3 27.3±5.1 30.1±4.
4 
116.8±3
6.8 
43.9± 
18.9 
86 
2 80±3.
7 
186.8±5
3.5 
15.4±4.8 27.4±11.
7 
12.2±3.9 44.4±48.
4 
40.7±6.
6 
161.5±4
2.6 
96±2
8.7 
96 
3 80.7±
3.4 
206.3±3
5.2 
20.4±5.7 37.8±15.
3 
15.7± 3.7 58.4±62 45.8±7.
9 
196.2±3
3.6 
154.6
±35.4 
48 
Hypoxia condition at 1.5% O2, 7 hours incubation 
1 80.7±
6.1 
150.6±4
9.1 
10.4± 1.5 18.4±4.6 11.3±3.1 31.1± 15 40.5±7.
9 
116.8±4
7.2 
63.3±
41 
92 
2 80.4±
3.7 
180.9±4
2.6 
15.1±5.2
5 
25.8±13.
1 
18±  3.5 34.9±21.
7 
50.4±10
.1 
170.4±3
9 
118.4
±52.3 
77 
3 81.3±
4.1 
201.1±3
5.1 
20.5±11.
5 
36.2±15.
1 
19.1±9.8 39.±19.3 61.9±11
.1 
204.5±1
6.1 
167± 
56.7 
34 
Hypoxia condition at 1.0% O2, 7 hours incubation 
1 81±5.
1 
153.8±5
7.1 
10.2±3.4 18±5.9 12.3±5.1 28.2±9.5 47.5±11
.6 
108.6±2
8.5 
84.3± 
36.2 
157 
2 80.3±
5 
181.9±5
8.7 
14.7±5.9 26.1±11 17.4±8.3 31.5±8.2 62.9± 
16.1 
174.1±3
2.3 
136.4
±51.9 
101 
3 80.8±
4.9 
199.5±4
1.7 
20.7±9.1 36.3±15.
1 
19.7±6.6 35.9±13.
1 
75±17.3 209± 
20.5 
188.2
±40.1 
58 
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Table S5. Fluorescence intensities and change in number of molecules of the mTOR 
kinase inhibition assay on U87 EFGRvIII bulk cell populations. The mean intensities and 
standard deviations (SD) are shown with or without addition of PP242, and at different 
O2. The molecular weights (in kDa) used in the calibrations are 120, 289, 44, 70, 52, 20 
and 20.3 for HIF-1α, p-mTOR(Ser2448), p-ERK1(T202/Y204), p-P70S6K(T389), MMP-
1, VEGF and IL-6, respectively. 
 
Protein    +         PP242 (3µM)       - Change in # of molecules 
(PP242+)  -  (PP242-) 
 mean SD mean SD mean SD 
U87 EGFRvIII normoxia condition at 21% O2, 7 hours incubation 
HIF-1α 94.9 13.4 107.0 13.3 -2.35E+07 3.7E+07 
p-mTOR 160.8 6.3 191.7 4.8 -3.59E+07 9.34E+06 
p-ERK1 247.0 4.4 194.1 6.5 2.56E+08 3.8E+07 
p-P70S6K 78.1 4.7 547.6 77.9 -2.23E+09 3.0E+08 
MMP-1 437.3 7.2 415.2 10.6 9.63E+07 5.6E+07 
VEGF 4858.6 189.5 4944.9 178.1 -1.70E+08 5.2+08 
IL-6 525.9 10.9 468.9 13.1 3.72E+08 1.1E+08 
U87 EGFRvIII hypoxia condition at 3.0% O2, 7 hours incubation 
HIF-1α 164.9 12.4 194.8 7.7 -5.29E+07 2.62E+07 
p-mTOR 143.3 5.9 163.3 4.3 -2.43E+07 9.06E+06 
p-ERK1 390.2 58.9 269.4 38.2 5.65E+08 3.29E+08 
p-P70S6K 204.3 18.2 389.8 65.9 -8.98E+08 3.13E+08 
MMP-1 546.2 23.4 463.6 17.2 3.50E+08 1.23E+08 
VEGF 7726.9 208.1 7980.9 360.4 -4.30E+08 7.07E+08 
IL-6 894.5 41.9 542 21.8 2.13E+09 2.75E+08 
U87 EGFRvIII hypoxia condition at 2.0% O2, 7 hours incubation 
HIF-1α 200.8 9.9 234.4 11.3 -5.73E+07 2.58E+07 
p-mTOR 149.7 5.4 152 5.8 -2.79E+06 9.75E+06 
p-ERK1 217.1 19.3 171 13.7 2.25E+08 1.16E+08 
p-P70S6K 121.6 18.4 256.4 34.5 -7.29E+08 2.07E+08 
MMP-1 540.3 18.6 402.1 26 5.94E+08 1.39E+08 
VEGF 7467.2 155.4 8137.6 110.4 -1.14E+09 3.26E+08 
IL-6 1066.9 69.1 452.7 31.7 3.64E+09 4.19E+08 
U87 EGFRvIII hypoxia condition at 1.5% O2, 7 hours incubation 
HIF-1α 210.8 9.6 285.4 14.4 -1.24E+08 2.87E+07 
p-mTOR 136.9 3.2 135.7 2.4 1.47E+06 5.13E+06 
p-ERK1 178.3 5.8 166.4 3.1 5.82E+07 3.25E+07 
p-P70S6K 115.9 7.6 373 92 -1.31E+09 4.32E+08 
MMP-1 337.4 16.8 313.8 11.8 1.07E+08 9.28E+07 
VEGF 8414.4 461.1 9851.6 495.1 -2.33E+09 1.10E+09 
IL-6 528 28.2 468.1 26.2 3.91E+08 3.01E+08 
U87 EGFRvIII hypoxia condition at 1.0% O2, 7 hours incubation 
HIF-1α 261.8 18.4 375.2 21.7 -1.78E+08 4.48E+07 
p-mTOR 99.8 4.3 119.7 3.8 -2.74E+07 7.99E+06 
p-ERK1 164.7 1.96 147.5 1.5 8.51E+07 1.22E+07 
p-P70S6K 54.3 7.9 338.8 53.8 -1.52E+09 2.61E+08 
MMP-1 289 12.9 316.3 17.1 -1.24E+08 9.76E+07 
VEGF 7567.1 179.1 10991.9 683.7 -5.54E+09 1.11E+09 
IL-6 1102.3 45.2 762.7 29.5 1.87E+09 2.91E+08 
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Table S6. Protein-protein covariance matrices at various pO2 levels from U87 EGFRvIII 
single cell data. The covariance matrices are symmetric, so only the upper half parts are 
shown. 
21% pO2 p-mTOR p-ERK1 p-p70S6K HIF-1α VEGF IL-6 MMP1 
p-mTOR 2.52E+07 2.11E+07 1.09E+07 1.19E+05 3.98E+07 2.29E+07 8.11E+06
p-ERK1 9.84E+07 2.37E+07 2.61E+06 -1.26E+07 -3.75E+06 1.24E+08
p-p70S6K  3.77E+07 6.46E+05 5.66E+07 1.98E+07 -9.52E+05
HIF-1α  8.82E+06 3.66E+07 3.36E+06 3.82E+07
VEGF  2.17E+09 5.68E+08 1.27E+08
IL-6  4.32E+08 -1.39E+07
MMP1   3.74E+09
3% pO2 p-mTOR p-ERK1 p-p70S6K HIF-1α VEGF IL-6 MMP1 
p-mTOR 1.74E+07 9.48E+06 6.62E+06 3.54E+06 1.96E+07 4.00E+06 1.06E+07
p-ERK1 7.69E+07 6.28E+06 9.49E+06 1.57E+08 2.27E+07 9.07E+06
p-p70S6K  1.48E+07 7.96E+06 3.47E+07 1.90E+07 4.55E+07
HIF-1α  3.42E+07 8.72E+07 5.73E+06 2.23E+07
VEGF  5.49E+09 6.09E+08 5.49E+08
IL-6  4.08E+08 1.42E+08
MMP1   6.75E+08
2% pO2 p-mTOR p-ERK1 p-p70S6K HIF-1α VEGF IL-6 MMP1 
p-mTOR 1.19E+07 1.08E+07 2.85E+06 1.54E+06 6.55E+07 3.65E+06 1.09E+07
p-ERK1 7.94E+07 1.03E+07 7.63E+06 5.18E+08 2.41E+07 3.15E+07
p-p70S6K  1.07E+07 5.76E+06 3.73E+08 1.23E+07 8.22E+06
HIF-1α  1.16E+07 2.96E+08 7.32E+06 1.98E+07
VEGF  6.13E+10 6.33E+08 2.87E+08
IL-6  7.95E+07 9.79E+06
MMP1   1.17E+08
1.5% pO2 p-mTOR p-ERK1 p-p70S6K HIF-1α VEGF IL-6 MMP1 
p-mTOR 6.04E+06 6.27E+06 5.36E+06 9.68E+05 1.51E+08 3.67E+06 3.10E+07
p-ERK1 1.37E+07 6.18E+06 2.83E+06 2.73E+07 8.39E+05 4.34E+07
p-p70S6K  1.86E+07 7.04E+06 1.73E+08 2.92E+07 1.07E+08
HIF-1α  5.27E+07 2.48E+08 6.03E+07 1.01E+08
VEGF  6.51E+10 6.37E+09 2.89E+07
IL-6  1.25E+09 2.02E+08
MMP1   1.52E+09
1% pO2 p-mTOR p-ERK1 p-p70S6K HIF-1α VEGF IL-6 MMP1 
p-mTOR 1.03E+07 1.67E+07 1.27E+07 7.24E+06 3.75E+06 1.47E+06 9.11E+06
p-ERK1 6.96E+07 1.96E+07 2.06E+07 3.56E+07 2.19E+07 2.09E+07
p-p70S6K  5.37E+07 6.61E+06 4.52E+08 2.28E+07 3.21E+07
HIF-1α  1.19E+08 1.14E+08 2.02E+07 3.48E+07
VEGF  8.66E+10 9.64E+08 9.25E+07
IL-6  3.14E+08 7.93E+07
MMP1   7.37E+08
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